Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Survivorship
Published in: Journal of Cancer Survivorship 6/2017

01-12-2017

Prostate cancer-related anxiety in long-term survivors after radical prostatectomy

Authors: Valentin H. Meissner, Kathleen Herkommer, Birgitt Marten-Mittag, Jürgen E. Gschwend, Andreas Dinkel

Published in: Journal of Cancer Survivorship | Issue 6/2017

Login to get access

Abstract

Purpose

Knowledge of the psychological distress of long- and very long-term (>10 years) prostate cancer (PC) survivors is limited. This study intended to examine the parameters influencing anxiety related to prostate-specific antigen (PSA) and PC in long-term survivors after radical prostatectomy.

Methods

We surveyed 4719 PC survivors from the German multicenter prospective database “Familial Prostate Cancer.” We evaluated the association of PC-related anxiety (MAX-PC) with sociodemographic characteristics, family history of PC, global health status/quality of life (EORTC QLQ-C30), depression and anxiety (PHQ-2; GAD-2), latest PSA level, time since radical prostatectomy, and current therapy.

Results

The survey participants’ mean age was 75.2 years (SD = 6.5). Median follow-up was 11.5 years, and 19.5% of participants had survived more than 15 years since the initial treatment. The final regression analysis found that younger age, lower global health status/quality of life, higher depression and anxiety scores, higher latest PSA level, and shorter time since radical prostatectomy predicted increased PSA-related anxiety and PC anxiety. Familial PC was predictive only of PSA anxiety (all p < 0.05). The final model explained 12% of the variance for PSA anxiety and 24% for PC anxiety.

Conclusions

PC-related anxiety remained relevant many years after prostatectomy and was influenced by younger age, psychological status, rising PSA level, and shorter time since initial treatment.

Implications for Cancer Survivors

Survivors with these characteristics are at increased risk of PC-related anxieties, which should be considered by the treating physician during follow-up.
Literature
1.
Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138:1388–400.CrossRefPubMed
2.
3.
4.
Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337–47.CrossRefPubMed
5.
Powell IJ, Meyskens FL. African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. Urology. 2001;57:178–81.CrossRefPubMed
6.
7.
Budäus L, Spethmann J, Isbarn H, et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int. 2011;108:1256–61.CrossRefPubMed
8.
9.
Lassemillante AC, Doi SA, Hooper JD, et al. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014;45:370–81.CrossRefPubMed
10.
11.
Olsson CE, Alsadius D, Pettersson N, et al. Patient-reported sexual toxicity after radiation therapy in long-term prostate cancer survivors. Br J Cancer. 2015;113:802–8.CrossRefPubMedPubMedCentral
12.
Kopp RP, Marshall LM, Wang PY, et al. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol. 2013;64:672–9.CrossRefPubMedPubMedCentral
13.
Gavin AT, Drummond JF, Donnelly C, et al. Patient-reported ‘ever had’ and ‘current’ long-term physical symptoms after prostate cancer treatments. BJU Int. 2015;116:397–406.CrossRefPubMedPubMedCentral
14.
Darwish-Yassine M, Berenji M, Wing D, et al. Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study. J Cancer Surviv. 2014;8:121–30.CrossRefPubMed
15.
van de Wal M, van Oort I, Schouten J, et al. Fear of cancer recurrence in prostate cancer survivors. Acta Oncol. 2016;55:821–7.CrossRefPubMed
16.
Dahl S, Cvancarova M, Dahl AA, et al. Work ability in prostate cancer survivors after radical prostatectomy. Scand J Urol. 2016;50:116–22.CrossRefPubMed
17.
Morris BB, Farnan L, Song L, et al. Treatment decisional regret among men with prostate cancer: racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCaP-NC). Cancer. 2015;121:2029–35.CrossRefPubMed
18.
Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–78.CrossRefPubMed
19.
20.
21.
Shen MJ, Nelson CJ, Peters E, et al. Decision-making processes among prostate cancer survivors with rising PSA levels: results from a qualitative analysis. Med Decis Mak. 2015;35:477–86.CrossRef
22.
23.
Klotz LH. PSAdynia and other PSA-related syndromes: a new epidemic—a case history and taxonomy. Urology. 1997;50:831–2.CrossRefPubMed
24.
Punnen S, Cowan JE, Chan JM, et al. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68:600–8.CrossRefPubMed
25.
Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4:e003901.CrossRefPubMedPubMedCentral
26.
Sharp L, O’Leary E, Kinnear H, et al. Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psycho-Oncology. 2016;25:282–91.CrossRefPubMed
27.
Dinkel A, Kornmayer M, Gschwend JE, et al. Influence of family history on psychosocial distress and perceived need for treatment in prostate cancer survivors. Familial Cancer. 2014;13:481–8.CrossRefPubMed
28.
Tavlarides AM, Ames SC, Diehl NN, et al. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psycho-Oncology. 2013;22:1328–35.CrossRefPubMed
29.
Roth A, Nelson CJ, Rosenfeld B, et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX–PC). Psychosomatics. 2006;47:340–7.CrossRefPubMed
30.
Roth AJ, Rosenfeld B, Kornblith AB, et al. The Memorial Anxiety Scale for Prostate Cancer. Validation of a new scale to measure anxiety in men with prosate cancer. Cancer. 2003;97:2910–8.CrossRefPubMed
31.
Venderbos LD, van den Bergh RC, Roobol MJ, et al. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psycho-Oncology. 2015;24:348–54.CrossRefPubMed
32.
Tan HJ, Marks LS, Hoyt MA, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. J Urol. 2016;195:1724–30.CrossRefPubMedPubMedCentral
33.
Tavlarides AM, Ames SC, Thiel DD, et al. Baseline and follow-up association of the MAX-PC in men with newly diagnosed prostate cancer. Psycho-Oncology. 2015;24:451–7.CrossRefPubMed
34.
Heck MM, Kron M, Gschwend JE, et al. Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer. Eur J Cancer. 2012;48:1312–7.CrossRefPubMed
35.
Lehmann C, Mehnert A, Schulte T, et al. Erfassung krebs-und behandlungsspezifischer Ängste bei Prostatakrebspatienten in der Rehabilitation: Der Memorial Angst-Fragebogen für Prostatakrebs (MAX-PC). Praxis Klinische Verhaltensmedizin und Rehabilitation. 2006;19:345–52.
36.
Mehnert A, Lehmann C, Schulte T, et al. Presence of symptom distress and prostate cancer-related anxiety in patients at the beginning of cancer rehabilitation. Onkologie. 2007;30:551–6.PubMed
37.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
38.
Kroenke K, Spitzer RL, Williams JB, et al. An ultra-brief screening scale for anxiety and depression: the PHQ–4. Psychosomatics. 2009;50:613–21.PubMed
39.
Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010;122:86–95.CrossRefPubMed
40.
Lamers RE, Cuypers M, Husson O, et al. Patients are dissatisfied with information provision: perceived information provision and quality of life in prostate cancer patients. Psycho-Oncology. 2016;25:633–40.CrossRefPubMed
41.
Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014;9:e102149.CrossRefPubMedPubMedCentral
42.
Vissers PA, Thong MS, Pouwer F, et al. The impact of comorbidity on health-related quality of life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv. 2013;7:602–13.CrossRefPubMed
43.
Drummond FJ, Kinnear H, O’Leary E, et al. Long-term health-related quality of life of prostate cancer survivors vary by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv. 2015;9:361–72.CrossRefPubMed
44.
Banks E, Byles JE, Gibson RE, et al. Is psychological distress in people living with cancer related to the fact of diagnosis, current treatment or level of disability? Findings from a large Australian study. Med J Aust. 2010;193(5 Suppl):S62–7.PubMed
45.
Roth A, Passik S. Anxiety in men with prostate cancer may interfere with effective management of the disease. Primary Care Cancer. 1996;16:30.
46.
Lofters A, Juffs HG, Pond GR, et al. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol. 2002;168:2516–20.CrossRefPubMed
47.
Hillen MA, de Haes HC, Smets EM. Cancer patients’ trust in their physician—a review. Psycho-Oncology. 2011;20:227–41.CrossRefPubMed
48.
Albright F, Stephenson RA, Agarwal N, et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2015;75:390–8.CrossRefPubMed
49.
Spencer BA, Babey SH, Etzioni DA, et al. A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma. Cancer. 2006;106:765–74.CrossRefPubMed
50.
Meiser B, Cowan R, Costello A, et al. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men’s screening uptake. Urology. 2007;70:738–42.CrossRefPubMed
51.
Cohen L, Fouladi RT, Babaian RJ, et al. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program. Cancer Epidemiol Biomark Prev. 2003;12:610–7.
Metadata
Title
Prostate cancer-related anxiety in long-term survivors after radical prostatectomy
Authors
Valentin H. Meissner
Kathleen Herkommer
Birgitt Marten-Mittag
Jürgen E. Gschwend
Andreas Dinkel
Publication date
01-12-2017
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 6/2017
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-017-0619-y

Other articles of this Issue 6/2017

Journal of Cancer Survivorship 6/2017 Go to the issue

Editorial

Introduction to special section on digital technology and cancer survivorship

OriginalPaper

Navigating cancer using online communities: a grounded theory of survivor and family experiences

OriginalPaper

A user-centred approach to developing bWell, a mobile app for arm and shoulder exercises after breast cancer treatment

OriginalPaper

Exploring the digital technology preferences of teenagers and young adults (TYA) with cancer and survivors: a cross-sectional service evaluation questionnaire

Review

Digital health behaviour change interventions targeting physical activity and diet in cancer survivors: a systematic review and meta-analysis

Review

Young adult cancer survivors and work: a systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits